Kymera says FDA grants Fast Track designation for KT-621 in eosinophilic asthma

• Kymera Therapeutics secured FDA Fast Track designation for KT-621, its oral STAT6 degrader, in moderate to severe eosinophilic asthma.
• Phase 2b BREADTH asthma study remains ongoing, with results expected in late 2027.
• Development plan also includes Phase 2b BROADEN2 trial in moderate to severe atopic dermatitis, with results expected by mid-2027.
• Earlier findings from BroADen Phase 1b in atopic dermatitis patients indicated improvement in asthma-related disease control in a subset with comorbid asthma.
• Fast Track status could support a faster path to later-stage registration studies if upcoming trials confirm clinical benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130700PRIMZONEFULLFEED9687917) on April 13, 2026, and is solely responsible for the information contained therein.